INTENSITY THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
INTENSITY THERAPEUTICS, INC. (INTS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-09-30 was $2.00.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.01, a 50.50% increase from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $3.01 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $3.01 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $4.00 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.00 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $2.00 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |